arXiv:2607.07611v1 Announce Type: new Abstract: Background: Graph neural networks improve computational prediction of polypharmacy side effects, but standard binary cross-entropy training allocates equal capacity to well-classified and difficult examples, potentially missing clinically significant interactions. We evaluated whether an asymmetric focal objective could improve multi-relational drug-drug interaction (DDI) prediction by emphasizing difficult positive interactions. Methods: ClinicalFocal loss was integrated into a relation-aware graph convolutional network using molecular fingerpri
The continuous advancements in AI and specifically Graph Neural Networks are enabling more sophisticated drug discovery and interaction prediction, addressing a long-standing challenge in pharmaceuticals.
Improved prediction of drug-drug interactions (DDIs) by AI can significantly reduce adverse drug events, accelerate drug development, and lead to safer, more effective polypharmacy treatments.
The application of asymmetric focal loss specifically to GNNs for DDI prediction offers a more robust and clinically relevant method for identifying critical interactions that might otherwise be missed.
- · Pharmaceutical companies
- · Patients
- · AI drug discovery platforms
- · Healthcare providers
- · Legacy drug safety analysis methods
- · Companies slow to adopt AI in R&D
More accurate and faster identification of potential drug risks and benefits.
Reduced healthcare costs associated with adverse drug reactions and improved patient outcomes.
Acceleration of personalized medicine pathways and the development of new combination therapies.
This signal links to a primary source. Continuum Brief monitors and indexes it as part of the live intelligence stream — we do not republish source content.
Read at arXiv cs.LG